인디애나의 비만 임상 시험
비만 관련 연구 24개가 인디애나 내 여러 지역에서 참여자를 모집하고 있습니다.
인디애나의 도시
공식 연구 텍스트(영어)
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Midwest Inst For Clin Res, Indianapolis
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- Midwest Inst For Clin Res, Indianapolis
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07668414A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- MediSphere Medical Research Center, LLC, Evansville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07595549AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
- Midwest Inst For Clin Res, Indianapolis
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT07339423A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Riley Hospital for Children, Indianapolis
피험자 모집 중3상
6세 ~ 17세 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06672549Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
피험자 모집 중3상
18세 ~ 70세 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
피험자 모집 중3상
18세 ~ 70세 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06937086A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Franciscan Physician Network - Indiana Heart Physicians, Indianapolis
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07783802Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Qualmedica Research, LLC, Evansville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07353931Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Cardiovascular Research of Northwest Indiana LLC, Munster
- Velocity Clinical Research - Valparaiso, Valparaiso
피험자 모집 중3상
45세 ~ 99세 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- DM Clinical Research - Indianapolis, Indianapolis
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07282600A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Evansville
- AURORA-1 Clinical Site, Indianapolis
- AURORA-1 Clinical Site, Valparaiso
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Evansville
- AURORA-2 Clinical Site, Indianapolis
- AURORA-2 Clinical Site, Valparaiso
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Midwest Cardiovascular Research And Education Foundation, Elkhart
- Ascension Medical Group, Indianapolis
- Cardiovascular Research of Northwest Indiana LLC, Munster
- 외 1개
피험자 모집 중3상
18세 ~ 99세 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT07037459A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Investigators Research Group, Brownsburg
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT06897475A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- The Indiana Clinical Trials Center, PC, Plainfield
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT06857942A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- Midwest Inst For Clin Res, Indianapolis
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07745504A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- IU Health - Riley Physicians Endo-Diab, Indianapolis
피험자 모집 중3상
8세 ~ 18세 · 모든 성별 · 2026. 8. 31. 업데이트됨 · NCT07253285The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
- Indiana University School of Medicine, Indianapolis
피험자 모집 중2상
11세 ~ 18세 · 모든 성별 · 2026. 8. 21. 업데이트됨 · NCT05414409A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Asha Clinical Rsch-Munster, LLC, Hammond
- Indiana University Health Methodist Hospital, Indianapolis
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT07567001A Sensory Strategy to Cut Sugary Beverages in African/American and Latine Adolescents
- Indiana University School of Public Health - Bloomington, Bloomington
- Indiana University Hospital, Indianapolis
- Purdue University, West Lafayette
피험자 모집 중건강한 지원자 환영
12세 ~ 18세 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT07223151Fibrosis Lessens After Metabolic Surgery
- Indiana University, Indianapolis
피험자 모집 중4상건강한 지원자 환영
18세 ~ 75세 · 모든 성별 · 2026. 7. 31. 업데이트됨 · NCT06374875Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- Indiana University, Indianapolis
피험자 모집 중
18세 ~ 45세 · 여성 · 2026. 6. 24. 업데이트됨 · NCT05124808Gut, Immune, and Vascular Health in Metabolically Healthy Obesity
- Health Professions Building, Muncie
피험자 모집 중건강한 지원자 환영
18세 ~ 55세 · 모든 성별 · 2026. 4. 30. 업데이트됨 · NCT07559227ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.